EQ
Equillium, Inc.
NASDAQ · USHealthcareBiotechnology
$2.47-4.63%
Price as of Jul 20, 2026
EQ financials
Equillium, Inc. financial statements
Annual and quarterly income statement, balance sheet and cash-flow history. On small screens, start with four periods and expand the table when needed.
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $0.00 | $41.1M | $36.1M | $15.8M |
| Cost of revenue | $116.0K | $0.00 | $0.00 | $0.00 |
| Gross profit | -$116.0K | $41.1M | $36.1M | $15.8M |
| Operating expenses | $23.6M | $49.4M | $50.6M | $77.8M |
| Operating income | -$23.6M | -$8.3M | -$14.5M | -$62.1M |
| Net income | -$22.4M | -$8.1M | -$13.3M | -$62.4M |
| EBITDA | -$22.3M | -$7.6M | -$12.1M | -$61.3M |
| Basic EPS | $-0.39 | $-0.23 | $-0.38 | $-3.19 |
| Diluted EPS | $-0.39 | $-0.23 | $-0.38 | $-3.19 |
| Balance sheet | ||||
| Cash & equivalents | $30.3M | $18.1M | $23.2M | $59.1M |
| Total assets | $31.9M | $25.6M | $50.5M | $78.4M |
| Total liabilities | $3.3M | $6.5M | $28.0M | $46.5M |
| Stockholders’ equity | $28.6M | $19.1M | $22.6M | $31.9M |
| Total debt | $719.0K | $384.0K | $824.0K | $10.2M |
| Net debt | -$29.6M | -$17.7M | -$22.4M | -$48.9M |
| Cash flow | ||||
| Operating cash flow | -$22.7M | -$19.0M | -$21.8M | -$8.7M |
| Capital expenditure | -$48.0K | -$85.0K | -$50.0K | -$279.0K |
| Free cash flow | -$22.8M | -$19.1M | -$21.8M | -$9.0M |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 |
| Share repurchases | $0.00 | $0.00 | -$260.0K | $0.00 |